Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia.
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0079022. doi: 10.1128/aac.00790-22. Epub 2022 Sep 1.
Bioactive forms of oral β-lactams were screened against Mycobacterium abscessus with and without the bioactive form of the oral β-lactamase inhibitor avibactam ARX1796. Sulopenem was equally active without avibactam, while tebipenem, cefuroxime, and amoxicillin required avibactam for optimal activity. Systematic pairwise combination of the four β-lactams revealed strong bactericidal synergy for each of sulopenem, tebipenem, and cefuroxime combined with amoxicillin in the presence of avibactam. These all-oral β-lactam combinations warrant clinical evaluation.
研究人员筛选了具有生物活性的口服β-内酰胺类药物，以评估其是否对脓肿分枝杆菌具有活性，同时还检测了具有生物活性的口服β-内酰胺酶抑制剂阿维巴坦对脓肿分枝杆菌的影响。结果显示，无阿维巴坦存在时，舒巴坦的活性相当，而替比培南、头孢呋辛和阿莫西林则需要阿维巴坦才能发挥最佳活性。系统的两两组合实验表明，在有阿维巴坦存在的情况下，舒巴坦、替比培南和头孢呋辛与阿莫西林联合使用均具有很强的杀菌协同作用。这些完全口服的β-内酰胺类药物组合值得进行临床评估。
